S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
Randomized Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
Sponsor: National Cancer Institute (NCI)
Listed as NCT02164916, this PHASE2 trial focuses on Colorectal Cancer and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 16 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
16 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
May 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — May 2023 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 11 earlier versions
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Completed → Active Not Recruiting
-
Jul 2020 — Aug 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2019 — Jul 2020 [monthly]
Active Not Recruiting PHASE2
-
Nov 2018 — Sep 2019 [monthly]
Active Not Recruiting PHASE2
-
Aug 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Nov 2017 — May 2018 [monthly]
Active Not Recruiting PHASE2
-
Mar 2017 — Nov 2017 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Mar 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Nov 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- Roche-Genentech
- SWOG Cancer Research Network
For direct contact, visit the study record on ClinicalTrials.gov .